Bristol-Myers Squibb Company (BMY)
| Market Cap | 89.80B |
| Revenue (ttm) | 47.70B |
| Net Income (ttm) | 5.05B |
| Shares Out | 2.04B |
| EPS (ttm) | 2.49 |
| PE Ratio | 17.75 |
| Forward PE | 6.90 |
| Dividend | $2.48 (5.62%) |
| Ex-Dividend Date | Oct 3, 2025 |
| Volume | 15,023,322 |
| Open | 43.96 |
| Previous Close | 43.41 |
| Day's Range | 43.25 - 44.14 |
| 52-Week Range | 42.96 - 63.33 |
| Beta | 0.36 |
| Analysts | Hold |
| Price Target | 57.64 (+30.64%) |
| Earnings Date | Oct 30, 2025 |
About BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthrit... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for BMY stock is "Hold." The 12-month stock price target is $57.64, which is an increase of 30.64% from the latest price.
News
Portal Innovations' John Flavin: Tariffs on pharma could raise costs and delay drug access
John Flavin, Portal Innovations founder and CEO, joins CNBC's 'Squawk on the Street' to discuss the Trump administration's proposed pharmaceutical tariffs, the impact on biotech startups and clinical ...
Bristol Myers to sell psoriasis drug at over 80% discount
Bristol Myers Squibb said on Thursday it will sell its psoriasis drug Sotyktu directly to cash-paying patients at a more than 80% discount to the drug's list price.
Bristol Myers Squibb Builds on Eliquis® (apixaban) Direct-to-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu® (deucravacitinib)
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Builds on Eliquis® (apixaban) Direct-to-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu®.
Bristol-Myers Squibb Company (BMY) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Transcript
Bristol-Myers Squibb Company (NYSE:BMY) Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum September 23, 2025 9:40 AM EDT Company Participants Lynelle Hoch - Presiden...
Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated a Significant Improvement in Minimal Residual Disease Negativity Rates in Relapsed or Refractory Multiple Myeloma
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies.
Buy Bristol Myers Squibb Stock At $45?
Bristol-Myers Squibb (NYSE: BMY) has considerably lagged behind the overall market, with its stock decreasing by 20% this year, while the S&P 500 index has risen by 14%. This drop can be attributed in...
Bristol Myers plans to launch schizophrenia drug in UK at list price equal to the US
Bristol Myers Squibb said on Monday that it plans to launch its schizophrenia treatment Cobenfy in the UK in 2026 at a price that is equal to its US list price.
Bristol Myers Squibb: Buy This Deep Bargain Before The Market Wakes To Income
Bristol Myers Squibb is a deep value opportunity, trading at a forward PE of 7x and offering a 5.5% dividend yield. BMY's next-gen portfolio drives double-digit growth, with blockbuster drugs like Reb...
Bristol Myers Squibb to Report Results for Third Quarter 2025 on October 30, 2025
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for Third Quarter 2025 on October 30, 2025.
Dividend Harvesting Portfolio Week 237: $23,700 Allocated, $2,573.68 In Projected Dividends
The Dividend Harvesting Portfolio reached all-time highs, up 34.27% on invested capital and producing $2,573.68 in forward annualized dividend income. Recent additions include NNN REIT, Bristol Myers,...
J&J's experimental psoriasis drug shows promise against Bristol's treatment
Johnson & Johnson said on Wednesday its experimental psoriasis drug has shown superior skin clearance compared to Bristol Myers Squibb's Sotyktu in two late-stage head-to-head trials.
Bristol Myers Squibb Announces Dividend
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Dividend.
Bristol Myers to sell 60% stake in China joint venture
U.S. drugmaker Bristol Myers Squibb said on Tuesday it has signed an agreement to sell its 60% ownership stake in a pharmaceutical joint venture in China.
10 Quality High Yield In Rose's Income Garden Portfolio: 5 Winners To Buy
Highlighting 10 S&P-rated companies with 4-7% yields, focusing on dividend growth, credit quality, and undervaluation. Pfizer, Alexandria RE, NNN REIT, AES Corp, and Bristol Myers are identified as un...
These stock-market experts don't love AI. Here's what they do recommend.
I'll bet you think that investment newsletters' most-recommended stock is Nvidia Corp., the AI-chip-producing giant whose stock has gained more than 30,000% over the past decade.
Bristol Myers Squibb to Participate in the Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in the Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum.
Meet 16 Ideal "Safer" September Dividend Dogs Of The S&P500
Sixteen of the thirty-eight highest-yield, 'safer' S&P 500 dividend stocks are highlighted as ready to buy, with adequate free cash flow supporting payouts. Analyst forecasts suggest top ten S&P 500 d...
BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy
BioNTech SE BNTX and Bristol Myers Squibb Co BMY shared interim Phase 2 data on pumitamig (BNT327/BMS986545) plus chemotherapy in patients with untreated extensive-stage small cell lung cancer (ES-SCL...
Bristol-Myers Squibb Company (BMY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Bristol-Myers Squibb Company (NYSE:BMY) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 8:30 AM EDT Company Participants Christopher Boerner - CEO & Chairman Adam Lenkowsky ...
BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial
A next-generation cancer immunotherapy by BioNTech and partner Bristol Myers Squibb led to encouraging tumour shrinkage in a mid-stage trial on small cell lung cancer that has started spreading, the G...
Bristol-Myers Squibb: Why Q2 Results Signal A Turning Point
Bristol-Myers Squibb continues to trade below $50, creating a divergence with strong performance from its oncology and cardiovascular franchises. So, sales of its "diamond" in the treatment of non-Hod...
Bristol-Myers Squibb: Growth Portfolio Surpasses Legacy, Driving Oncology And Immunology Leadership
Bristol-Myers Squibb is a Strong Buy at current levels, with a $54 price target and attractive 5.2% dividend yield. The company's innovative growth portfolio is gaining traction, offsetting legacy dec...
Bristol Myers Squibb: A 5% Yield And Single-Digit P/E Still Look Good
Visa has demonstrated why it remains the market leader in the global payment processor market, thanks to its robust, profitable growth cadence.
Bristol-Myers Squibb: Buy Before The Market Realizes Its Folly
Bristol-Myers Squibb stock remains undervalued, even though it faces significant LOE risks through 2028. BMY's growth portfolio is gaining credence, helping to mitigate the risks due to the decline in...
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 4% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...